RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas

Tarnowski,Maciej; Schneider,Gabriela; Amann,Gabriele; Clark,Geoffrey; Houghton,Peter; Barr,Frederic  G.; Kenner,Lukas; Ratajczak,Mariusz  Z.; Kucia,Magda

doi:10.3892/ijo.2012.1536

RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas

Authors:
- Maciej Tarnowski
- Gabriela Schneider
- Gabriele Amann
- Geoffrey Clark
- Peter Houghton
- Frederic G. Barr
- Lukas Kenner
- Mariusz Z. Ratajczak
- Magda Kucia
View Affiliations

Affiliations: Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA, Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, World Children's Cancer Center, Columbus, OH, USA, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Published online on: June 28, 2012 https://doi.org/10.3892/ijo.2012.1536
Pages: 995-1004

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The involvement of the Ras superfamily of GTPases in the pathogenesis of rhabdomysarcoma (RMS) is not well understood. While mutant H-Ras leads to embryonal RMS (ERMS) formation in experimental animals and in Costello syndrome patients, no data exists on the potential role of Ras GTPases in the pathogenesis of alveolar RMS (ARMS). To address this issue better, we focused on the role of the GTP exchange factor RasGRF1 in this process. We observed that, in comparison to normal skeletal muscle cells, RasGRF1 mRNA is upregulated in the majority of human ARMS cell lines and subsequently confirmed its high expression in patient samples. By employing confocal microscopy analysis, we observed RasGRF1 accumulation in cell filopodia, which suggests its involvement in ARMS cell migration. Furthermore, we observed that RasGRF1 becomes phosphorylated in ARMS after stimulation by several pro-metastatic factors, such as SDF-1 and HGF/SF, as well as after exposure to growth-promoting Igf-2 and insulin. More importantly, activation of RasGRF1 expression correlated with activation of p42/44 MAPK and AKT. When the expression of RasGRF1 was down-regulated in ARMS cells by an shRNA strategy, these RasGRF1-kd RMS cells did not respond to stimulation by SDF-1, HGF/SF, Igf-2 or insulin by phosphorylation of p42/44 MAPK and AKT and lost their chemotactic responsiveness; however, their adhesion was not affected. We also observed that RasGRF1-kd ARMS cells proliferated at a very low rate in vitro, and, more importantly, after inoculation into immunodeficient SCID/beige inbred mice they formed significantly smaller tumors. We conclude that RasGRF1 plays an important role in ARMS pathogenesis and is a new potential therapeutic target to inhibit ARMS growth.

View Figures

View References

1	Barr FG, Galili N, Holick J, Biegel JA, Rovera G and Emanuel BS: Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 3:113–117. 1993. View Article : Google Scholar : PubMed/NCBI
2	Collins MH, Zhao H, Womer RB and Barr FG: Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. Med Pediatr Oncol. 37:83–89. 2001. View Article : Google Scholar
3	Hazelton BJ, Houghton JA, Parham DM, et al: Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res. 47:4501–4507. 1987.PubMed/NCBI
4	Kelly KM, Womer RB and Barr FG: PAX3-FKHR and PAX7-FKHR gene fusions in rhabdomyosarcoma. J Pediatr Hematol Oncol. 20:517–518. 1998. View Article : Google Scholar : PubMed/NCBI
5	Sandberg AA, Stone JF, Czarnecki L and Cohen JD: Hematologic masquerade of rhabdomyosarcoma. Am J Hematol. 68:51–57. 2001. View Article : Google Scholar : PubMed/NCBI
6	Sharp R, Recio JA, Jhappan C, et al: Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med. 8:1276–1280. 2002. View Article : Google Scholar : PubMed/NCBI
7	Gordon T, McManus A, Anderson J, et al: Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study. Med Pediatr Oncol. 36:259–267. 2001. View Article : Google Scholar : PubMed/NCBI
8	Charytonowicz E, Cordon-Cardo C, Matushansky I and Ziman M: Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett. 279:126–136. 2009. View Article : Google Scholar : PubMed/NCBI
9	Hahn H, Wojnowski L, Specht K, et al: Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem. 275:28341–28344. 2000. View Article : Google Scholar : PubMed/NCBI
10	Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D and Somers GR: Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol. 12:127–135. 2009. View Article : Google Scholar : PubMed/NCBI
11	Rikhof B, De Jong S, Suurmeijer AJ, Meijer C and van der Graaf WT: The insulin-like growth factor system and sarcomas. J Pathol. 217:469–482. 2009. View Article : Google Scholar : PubMed/NCBI
12	Wang W, Kumar P, Epstein J, Helman L, Moore JV and Kumar S: Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res. 58:4426–4433. 1998.PubMed/NCBI
13	Naini S, Etheridge KT, Adam SJ, et al: Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res. 68:9583–9588. 2008. View Article : Google Scholar : PubMed/NCBI
14	Innocenti M, Zippel R, Brambilla R and Sturani E: CDC25(Mm)/Ras-GRF1 regulates both Ras and Rac signaling pathways. FEBS Lett. 460:357–362. 1999. View Article : Google Scholar : PubMed/NCBI
15	Lavagni P, Indrigo M, Colombo G, et al: Identification of novel RasGRF1 interacting partners by large-scale proteomic analysis. J Mol Neurosci. 37:212–224. 2009. View Article : Google Scholar : PubMed/NCBI
16	Rossman KL, Der CJ and Sondek J: GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 6:167–180. 2005. View Article : Google Scholar : PubMed/NCBI
17	Langenau DM, Keefe MD, Storer NY, et al: Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 21:1382–1395. 2007. View Article : Google Scholar : PubMed/NCBI
18	Shome D, Honavar SG, Reddy VA and Vemuganti GK: Orbital embryonal rhabdomyosarcoma in association with neurofibromatosis type 1. Ophthal Plast Reconstr Surg. 23:147–148. 2007. View Article : Google Scholar : PubMed/NCBI
19	Yang P, Grufferman S, Khoury MJ, et al: Association of childhood rhabdomyosarcoma with neurofibromatosis type I and birth defects. Genet Epidemiol. 12:467–474. 1995. View Article : Google Scholar : PubMed/NCBI
20	Jung A, Bechthold S, Pfluger T, Renner C and Ehrt O: Orbital rhabdomyosarcoma in Noonan syndrome. J Pediatr Hematol Oncol. 25:330–332. 2003. View Article : Google Scholar : PubMed/NCBI
21	Khan S, McDowell H, Upadhyaya M and Fryer A: Vaginal rhabdomyosarcoma in a patient with Noonan syndrome. J Med Genet. 32:743–745. 1995. View Article : Google Scholar : PubMed/NCBI
22	Gripp KW, Scott CI Jr, Nicholson L, et al: Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet. 108:80–87. 2002. View Article : Google Scholar : PubMed/NCBI
23	Feingold M: Costello syndrome and rhabdomyosarcoma. J Med Genet. 36:582–583. 1999.PubMed/NCBI
24	O’Neal JP, Ramdas J, Wood WE and Pellitteri PK: Parameningeal rhabdomyosarcoma in a patient with Costello syndrome. J Pediatr Hematol Oncol. 26:389–392. 2004.
25	Tidyman WE and Rauen KA: The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev. 19:230–236. 2009. View Article : Google Scholar : PubMed/NCBI
26	Hettmer S and Wagers AJ: Muscling in: uncovering the origins of rhabdomyosarcoma. Nat Med. 16:171–173. 2010. View Article : Google Scholar : PubMed/NCBI
27	Shin DM, Zuba-Surma EK, Wu W, et al: Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells. Leukemia. 23:2042–2051. 2009.PubMed/NCBI
28	Stratton MR, Fisher C, Gusterson BA and Cooper CS: Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 49:6324–6327. 1989.
29	Ren YX, Finckenstein FG, Abdueva DA, et al: Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res. 68:6587–6597. 2008. View Article : Google Scholar : PubMed/NCBI
30	Libura J, Drukala J, Majka M, et al: CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood. 100:2597–2606. 2002. View Article : Google Scholar : PubMed/NCBI
31	Jankowski K, Kucia M, Wysoczynski M, et al: Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 63:7926–7935. 2003.
32	Grymula K, Tarnowski M, Wysoczynski M, et al: Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer. 127:2554–2568. 2010. View Article : Google Scholar : PubMed/NCBI
33	Tarnowski M, Grymula K, Reca R, et al: Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer Res. 8:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
34	Ratajczak MZ, Shin DM, Liu R, et al: Epiblast/germ line hypothesis of cancer development revisited: lesson from the presence of Oct-4⁺ cells in adult tissues. Stem Cell Rev. 6:307–316. 2010. View Article : Google Scholar : PubMed/NCBI
35	Casola S, Pedone PV, Cavazzana AO, et al: Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene. 14:1503–1510. 1997. View Article : Google Scholar : PubMed/NCBI
36	Anderson J, Gordon A, McManus A, Shipley J and Pritchard-Jones K: Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia. 1:340–348. 1999. View Article : Google Scholar : PubMed/NCBI
37	Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K and Sapienza C: A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA. 86:7480–7484. 1989. View Article : Google Scholar : PubMed/NCBI
38	Zhan S, Shapiro DN and Helman LJ: Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest. 94:445–448. 1994. View Article : Google Scholar : PubMed/NCBI
39	Taichman RS, Wang Z, Shiozawa Y, et al: Prospective identification and skeletal localization of cells capable of multilineage differentiation in vivo. Stem Cells Dev. 19:1557–1570. 2010. View Article : Google Scholar : PubMed/NCBI
40	De la Puente A, Hall J, Wu YZ, et al: Structural characterization of Rasgrf1 and a novel linked imprinted locus. Gene. 291:287–297. 2002.PubMed/NCBI
41	Yoon B, Herman H, Hu B, et al: Rasgrf1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker. Mol Cell Biol. 25:11184–11190. 2005. View Article : Google Scholar : PubMed/NCBI
42	Yoon BJ, Herman H, Sikora A, Smith LT, Plass C and Soloway PD: Regulation of DNA methylation of Rasgrf1. Nat Genet. 30:92–96. 2002. View Article : Google Scholar : PubMed/NCBI
43	Martegani E, Vanoni M, Zippel R, et al: Cloning by functional complementation of a mouse cDNA encoding a homologue of CDC25, a Saccharomyces cerevisiae RAS activator. EMBO J. 11:2151–2157. 1992.PubMed/NCBI
44	Buchsbaum R, Telliez JB, Goonesekera S and Feig LA: The N-terminal pleckstrin, coiled-coil, and IQ domains of the exchange factor Ras-GRF act cooperatively to facilitate activation by calcium. Mol Cell Biol. 16:4888–4896. 1996.PubMed/NCBI
45	Chevallier-Multon MC, Schweighoffer F, Barlat I, et al: Saccharomyces cerevisiae CDC25 (1028–1589) is a guanine nucleotide releasing factor for mammalian ras proteins and is oncogenic in NIH3T3 cells. J Biol Chem. 268:11113–11118. 1993.PubMed/NCBI
46	Leaner VD, Donninger H, Ellis CA, Clark GJ and Birrer MJ: p75-Ras-GRF1 is a c-Jun/AP-1 target protein: its up regulation results in increased Ras activity and is necessary for c-Jun-induced nonadherent growth of Rat1a cells. Mol Cell Biol. 25:3324–3337. 2005. View Article : Google Scholar : PubMed/NCBI
47	Font de Mora J, Esteban LM, Burks DJ, et al: Ras-GRF1 signaling is required for normal beta-cell development and glucose homeostasis. EMBO J. 22:3039–3049. 2003.PubMed/NCBI
48	Guerrero C, Rojas JM, Chedid M, et al: Expression of alternative forms of Ras exchange factors GRF and SOS1 in different human tissues and cell lines. Oncogene. 12:1097–1107. 1996.PubMed/NCBI
49	Forlani G, Baldassa S, Lavagni P, Sturani E and Zippel R: The guanine nucleotide exchange factor RasGRF1 directly binds microtubules via DHPH2-mediated interaction. FEBS J. 273:2127–2138. 2006. View Article : Google Scholar : PubMed/NCBI
50	Arozarena I, Matallanas D, Berciano MT, et al: Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors. Mol Cell Biol. 24:1516–1530. 2004. View Article : Google Scholar : PubMed/NCBI